Postes actifs de Melanie Kelly
Sociétés | Poste | Début | Fin |
---|---|---|---|
Panag Pharma, Inc.
Panag Pharma, Inc. Pharmaceuticals: MajorHealth Technology Panag Pharma, Inc. engages in the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Its product Topical A, provides a new approach to the treatment of chronic pain and inflammation. The company was founded by Mary Lynch, Melanie Kelly, Christian Lehmann, and Orlando Hung and is headquartered in Halifax, Canada. | Directeur Technique/Scientifique/R&D | - | - |
Fondateur | - | - |
Historique de carrière de Melanie Kelly
Anciens postes connus de Melanie Kelly
Sociétés | Poste | Début | Fin |
---|---|---|---|
TALLC Corp., Inc.
TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada. | Fondateur | - | - |
Statistiques
Internationale
Canada | 3 |
Opérationnelle
Founder | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Panag Pharma, Inc.
Panag Pharma, Inc. Pharmaceuticals: MajorHealth Technology Panag Pharma, Inc. engages in the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Its product Topical A, provides a new approach to the treatment of chronic pain and inflammation. The company was founded by Mary Lynch, Melanie Kelly, Christian Lehmann, and Orlando Hung and is headquartered in Halifax, Canada. | Health Technology |
TALLC Corp., Inc.
TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada. | Health Technology |
- Bourse
- Insiders
- Melanie Kelly
- Expérience